Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Addex (SWX:ADXN) and Merck (NYSE:MRK) partnered to develop ADX63365 to treat schizophrenia and other undisclosed indications. The positive allosteric modulator of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury